Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

SanofiNASDAQ: SNY

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables turns negative

Q2 FY2026 accounts receivables was -€31.5M, compared with €0 a year earlier. Trailing-twelve-month accounts receivables was €753.5M. Over 3 fiscal years it compounded at +39.5% a year.

Context

  • Accounts receivables amounted to 2.9% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Accounts receivables grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -€31.5M or moves back toward the trailing-twelve-month quarterly average of €188.38M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€31.5M— QoQ
Last fiscal yearDec 2025
-€1.36B+4744.8% YoY
LTMJun 2026
€753.5M— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+4744.8%——
3-year CAGR+39.5%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

EUR · from the cash flow

Latest · FY2025
(1.36B) EUR
Year-over-year change
-4744.8%

Accounts Receivables vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Accounts receivables amounts to 1.5% of revenue for SNY, versus a peer median of 0.3%.
SNY Competitors
Accounts Receivables for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMGNAmgen Inc.LTM Jun 2026$1.53B USD-9.4%+53.1%4.0%
MRKMerck & Co., Inc.LTM Jun 2026$1.09B USD—+19.2%1.6%
SNYSanofiLTM Jun 2026€753.5M EUR—+39.5%1.5%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$678M USD+102.4%-23.7%1.4%
NVSNovartis AGLTM Jun 2026$672.78M USD-6.6%+41.7%1.2%
GILDGilead Sciences, Inc.LTM Jun 2026$154M USD-833.3%-3.3%0.5%
LLYEli Lilly and CompanyLTM Jun 2026$0 USD—+185.9%0.0%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding SNY) —-8.0%+30.4%0.3%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income6.22B7.97B5.06B5.5B5.57B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
Deferred Income Tax(356M)(529M)(1.23B)(802M)(2.75B)
Stock-Based Compensation244M0000
Change in Working Capital1.41B(794M)413M(615M)2.03B
Accounts Receivables185M(500M)(472M)(28M)(1.36B)
Inventory(357M)(918M)(866M)(477M)(44.02M)
Accounts Payables451M340M258M789M449.17M
Other Working Capital1.13B284M1.49B(899M)2.98B
Other Non-Cash Items(349M)771M1.59B1.42B1.61B
Operating Cash Flow10.52B10.53B10.26B9.08B12.13B
Capital Expenditures(2.04B)(2.1B)(2.91B)(3.2B)(1.99B)
Acquisitions (Net)(5.59B)(1.34B)(2.63B)(2.52B)955.91M
Purchases of Investments(311M)(488M)(134M)0(11.37B)
Sales of Investments718M0000
Other Investing Activities(68M)1.86B(533M)1.35B11.74B
Investing Cash Flow(7.3B)(2.08B)(6.2B)(4.41B)(2.76B)
Debt Repayment(2.8B)(1.23B)(3.14B)(894M)2.07B
Common Stock Issued186M188M195M187M199.76M
Common Stock Repurchased(382M)(497M)(593M)(302M)(5.68B)
Dividends Paid(4.01B)(4.17B)(4.45B)(4.7B)(5.39B)
Other Financing Activities(48M)(111M)(63M)(50M)(472.87M)
Financing Cash Flow(7.06B)(5.82B)(8.05B)(5.76B)(9.26B)
Effect of Forex Changes15M8M(32M)(13M)862.16M
Net Change in Cash(3.82B)2.64B(4.03B)(1.27B)970.51M
Free Cash Flow8.48B8.42B7.35B5.89B10.14B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.